Published 2017-07-20
Riyan Adi Kurnia Syah Mirsya Warli Ginanda Putra Siregar


Objective: Course of the disease of kidney cancer may be unpredictable. For example, between 4.2–7.1% of patients with tumours ≤4 cm that are usually slow-growing may have metastases at diagnostic and are at an elevated risk of disease-specific mortality. Conversely, as many as 40% of patients with lymph node metastases were diagnosed at nephrectomy are alive 5 year after surgery. Several approaches have been proposed to help predict the course of disease of kidney cancer and to distinguish between poor and favourable risk patients. In this study, we review the existing prognostic factors and compared with established prognostic models. Material & methods: This is an analytic descriptive study of all kidney cancer patients treated at Haji Adam Malik Hospital between 2011 and 2015. Individual patient data was collected from medical record and compiled. Results: The number of samples analyzed in this study were 38 patients. We found seven patients remain alive of the entire sample. From the results of the univariate test, the factors that have a significant relationship with the mortality rate were low KPS (<80), weight loss, and nephrectomy. From the results of multivariate analysis, nephrectomy is the only prognostic factor in patients with kidney cancer. Mortality rate was 0.056x lower in patients who underwent nephrectomy compared with patients who did not underwent nephrectomy. Conclusion: Despite the high mortality rate that is found in this study, nephrectomy still has a place in kidney cancer management, even in patients with advanced stage.



kidney cancer


Lughezzani G, Jeldres C, Isbarn H. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol. 2009; 182: 1287–93.

Karakiewicz P, Trinh Q-D, Bhojani N. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: Prognostic indicators of disease-specific survival. Eur Urol. 2007; 51: 1616–24.

International Agency for Research on Cancer. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Globocan; 2012. Download from

Lipworth L, Tarone R-E, McLaughlin J-K. The epidemiology of renal cell carcinoma. J Urol. 2006; 176: 2353–8.

Pantuck A-J, Zisman A, Belldegrun A-S. The changing natural history of renal cell carcinoma. J Urol. 2001; 166: 1611–23.

Figlin R. Renal cell carcinoma: Management of advanced disease. J Urol. 1999; 161: 381–6.

Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62: 10–29.

Karakiewicz P, Jeldres C, Suardi N. Age at diagnosis is a determinant factor of renal cell carcinoma–specific survival in patients treated with nephrectomy. Can Urol Assoc J. 2008; 2(6): 610–7.

May M, Aziz A, Zigeuner R. Gender differences in clinic pathological features and survival in surgically treated patients with renal cell carcinoma: An analysis of the multi center CORONA database. World J Urol; 2013.

Motzer R, Mazumdar M, Bacik J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530–40.

Leibovich B, Han K-R, Bui M. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer. 2003; 98: 2566–75.

Negrier S, Gomez F, Douillard J-Y. Prognostic factor of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d’Immunitherapie. World J Urol. 2005; 23: 161–5.

Ingimarsson J, Sigurdsson M, Hardarson S. The impact of tumor size on the probability of synchronous metastasis and survival in renal cell carcinoma patients: A population-based study. BMC Urology. 2014; 14: 72.

Flanigan R, Salmon S, Blumenstein B. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345(23): 1855–9.

Mickisch G, Poppel H, Prijck L. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomized trial. Lancet. 2001; 358: 966–70.

Zisman A, Pantuck A, Dorey F. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002; 20: 1368–74.

Vasselli J, Yang J, Linehan W. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001; 166: 68–72.

Keegan K, Schupp C, Chamie K. Histopathology of surgically treated renal cell carcinoma: Survival differences by subtype and stage. J Urol. 2012; 188: 391–7.

Negrier S, Escudier B, Gomez F. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d’Immunotherapie. Annals of Oncology. 2002; 13: 1460–8.

Escudier B, Choueiri T, Oudard S. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol. 2007; 178: 1901–5.

Mekhail T, Abou-Jawde R, BouMerhi G. Validation and extension of the memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 832–41.

Atzpodien J, Royston P, Wandert T. Metastatic renal carcinoma comprehensive prognostic system. British Journal of Cancer. 2003; 88: 348–53.

Donskov F, Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 1997–2005.

Kim Y, Kim J, Chung H-T. Brain metastasis from renal cell carcinoma. Prog Neurol Surg. 2012; 25: 163–75.

Heng D, Xie W, Regan M. Prognostic factor for overall survival in patients with metastatic eenal cell carcinoma treated with vascular endothelial growth factor–targeted agents: Results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794–9.

Symbas N, Townsend M, El-Galley R. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000; 86: 203–7.

Suppiah R, Shaheen P, Elson P. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006; 107: 1793–800.

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University